Arrowhead Pharmaceuticals to Present New Phase 3 Data at ESC 2024 from PALISADE Study of Plozasiran in Patients with Familial Chylomicronemia Syndrome

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will present new Phase 3 clinical data from the PALISADE study of plozasiran (ARO-APOC3) at the European Society of Cardiology (ESC) Congress 2024, being held in London August 30 through September 2, 2024. The company will also host a virtual analyst and investor event on September 3, 2024, at 8:00 am EDT.

Details about the ESC presentation are listed below.

European Society of Cardiology Congress 2024 – August 30 - September 2, 2024

Title: A phase 3 study to evaluate the efficacy and safety of ARO-APOC3 in adults with familial chylomicronemia syndrome
Date/Time: September 2, 2024, 11:36 am BST
Presenter: Professor Gerald Watts, University of Western Australia
Session: Small trials, trial updates, and other studies on lipid therapy
Session Type: Late Breaking Science

The analyst and investor event on September 3, 2024, at 8:00 am EDT will feature an encore presentation of the ESC 2024 data by Professor Watts, and will include discussion by Arrowhead management. To register for the event, please visit: https://lifescievents.com/event/arrowheadpharma/. The live event and an archived webcast may also be accessed on the Events and Presentations page in the Investors section of the Arrowhead website.

Expert Bio

Gerald F Watts, DSc, DM, PhD, FRCP, FRACP, FCSANZ, is Winthrop Professor of Cardio-metabolic Medicine in the University of Western Australia. Dr. Watts trained at Imperial & King’s College, London University, and was a scholar at Wolfson College, Oxford University. He is a senior consultant physician, specializing in the rapidly developing field of cardio-metabolic medicine, and current chair of the Familial Hypercholesterolemia Australasia Network. He leads the Cardio-metabolic Service in the Departments of Cardiology and Internal Medicine at Royal Perth Hospital and is Winthrop Professor of Cardio-metabolic Medicine in the University of Western Australia. Research interests include fundamental and applied aspects of lipid disorders and cardiovascular prevention and improving healthcare delivery for patients with high-risk dyslipidemias, in particular familial hypercholesterolemia and hyperchylomicronemia. He has supervised several Masters, MD and PhD students and post-doctoral research fellows, and holds several research grants, with multiple collaborations.